Intellia Therapeutics has entered into a US$400 million non-dilutive senior secured term loan facility with OrbiMed, including a US$75 million initial draw and milestone-based tranches primarily linked to lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, with full details to follow in an SEC Form 8-K filing. This financing structure, which ties most of the available capital to lonvo-z development milestones, highlights how central that program has become to Intellia's funding and execution plans. The loan directly targets the biggest near-term catalyst, lonvo-z's path to approval and launch, while partially easing but not eliminating funding risk over the next few years. Intellia's narrative projects $644.6 million revenue and $117.5 million earnings by 2029, requiring 121.3% yearly revenue growth and a $517.5 million earnings increase from -$400.0 million today. Some optimistic analysts had assumed revenue could reach about US$3.0 billion by 2029, but the FDA clinical hold on nex-z shows how quickly expectations can shift.
Intellia Therapeutics IncSecures $400M non-dilutive loan tied to lonvo-z milestones, easing funding risk for key program.
Shanghai Henlius Biotech IncOrbiMed provides $400M loan, a financial investment in Intellia.
